🗞️ Why in News The Department of Pharmaceuticals announced on 8 October 2026 that the Government has approved a cap on trade margins for non-scheduled anti-cancer drugs: the margins added in supply and sale will be limited to 30% of the Maximum Retail Price (MRP). The measure is expected to cut prices by up to 70% and save patients ₹2,500 crore a year. It is not yet in force: an expert committee under the Directorate General of Health Services (DGHS) will finalise the list of medicines, and the National Pharmaceutical Pricing Authority (NPPA) will then decide and issue the notification.
New to this topic? Start here: the basics in plain words (revision card 1 of 6)
What the Government Approved
| Item | Detail |
|---|---|
| Drugs covered | Non-scheduled anti-cancer drugs, on a list the DGHS expert committee will finalise |
| The cap | Margins in supply and sale limited to 30% of MRP |
| Expected effect | Prices down by up to 70%; patients save ₹2,500 crore a year |
| Categories | Branded and generic, domestically produced and imported, patented and non-patented |
| Supply safeguard | Manufacturers must maintain their current production levels |
| Next steps | DGHS expert committee finalises the list; NPPA decides and issues the notification |
A simple way to read the cap: on a medicine with an MRP of ₹1,000, the margins added on the way to the patient could together come to at most ₹300.
Scheduled and Non-Scheduled: the Gap Being Closed
For background, medicine prices are regulated by the NPPA under the Drugs (Prices Control) Order (DPCO), 2013, which our 1 October editorial explainer notes is issued under the Essential Commodities Act, 1955. The Department’s release sets out the gap this decision fills: “Essential cancer medicines included in the scheduled list are already subject to strict government-set ceiling prices. The new decision extends price protection to non-scheduled cancer medicines, which are outside that list, by limiting the margins added before they reach patients.”
| Scheduled cancer medicines | Non-scheduled cancer medicines | |
|---|---|---|
| Control until now | Government-set ceiling prices | No ceiling price |
| After this decision | Unchanged | Margins capped at 30% of MRP, once NPPA notifies |
| What is controlled | The final price | The margin added before the patient buys |
Trade margin, in plain words: the margins added as a medicine moves through the supply chain before it reaches the patient, here capped as a share of the MRP. The concern the release records is “the large gap between the price at which medicines are purchased for sale and the MRP charged to consumers”.
Why Now: What the Data Showed
- Burden: cancer incidence is rising, with about 60 people per one lakh population affected, and families often pay from their own pockets.
- Mark-ups: NPPA’s analysis of market data found that non-scheduled anti-cancer medicines carry an average price mark-up of about 170%, reaching 700% or more in some cases.
- Where you buy matters: prices vary between a retail pharmacy, a hospital pharmacy and an online pharmacy.
- Who complained: State authorities, including Maharashtra, Rajasthan and Karnataka, along with patients and civil society, raised concerns over the gap between the purchase price and the MRP.
For context, the question has also been before the Supreme Court. On 22 September, a Bench of Justices Vikram Nath and Sandeep Mehta called a tenfold gap between the MRP and the price to retailer of a cancer drug “broad daylight dacoity” (our 23 September report has the background). The Department’s release does not mention the case.
The 2019 Precedent
In February 2019, on the Government’s direction, the NPPA capped trade margins on 42 selected non-scheduled anti-cancer drugs under Paragraph 19 of the DPCO, 2013. According to the release, that decision reduced MRPs by up to 91%, with reported annual savings of ₹984 crore across 526 brands.
| February 2019 | Approved, announced 8 October 2026 | |
|---|---|---|
| Coverage | 42 selected non-scheduled anti-cancer drugs | Non-scheduled anti-cancer drugs on the DGHS list |
| Effect | MRPs down up to 91% | Prices expected down up to 70% |
| Savings | ₹984 crore a year (reported), 526 brands | ₹2,500 crore a year (expected) |
| Status | Done | Awaits the list and the NPPA notification |
How the Cap Will Reach Patients
How the cancer-drug margin cap reaches patients
Approved, not yet notified: a list first, then the NPPA notification.
The release adds one safeguard against shortages: manufacturers of non-scheduled anti-cancer drugs “will be required to maintain their current production levels”.
What to Watch
- The list. Which drugs the DGHS committee includes decides how much of the ₹2,500 crore saving is real.
- The notification. No date has been given; until NPPA notifies, prices do not change.
- Availability. A margin cap squeezes distributors and hospital pharmacies. The production rule is meant to stop drugs from disappearing; enforcement will be the test.
- Hospital billing. Prices differ by channel, so whether hospital pharmacies pass on the cut matters as much as the cap itself.
UPSC Relevance
GS Paper 2: health, access to medicines, issues relating to the development and management of the health sector; government policies and interventions.
GS Paper 3: pricing and regulation; inclusive growth; out-of-pocket expenditure.
Prelims: NPPA, DPCO 2013, scheduled versus non-scheduled drugs, trade margin, Paragraph 19.
Mains: price control versus availability; trade margin rationalisation as a tool; the role of the courts and the executive in drug pricing.
📌 Facts Corner, Knowledgepedia
Prelims, statement-ready facts:
- Announced 8 October 2026 by the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers.
- Trade margins on non-scheduled anti-cancer drugs capped at 30% of MRP.
- Expected: prices down up to 70%; savings ₹2,500 crore a year.
- DGHS expert committee finalises the list; NPPA issues the notification.
- Covers branded and generic, domestic and imported, patented and non-patented drugs; makers must maintain current production.
- February 2019: NPPA capped trade margins on 42 non-scheduled anti-cancer drugs under Paragraph 19, DPCO 2013; MRPs down up to 91%, ₹984 crore a year, 526 brands.
Prelims, the traps:
- Scheduled cancer drugs already have ceiling prices; this cap is for non-scheduled ones.
- The cap is approved, not yet notified; prices change only after NPPA notifies.
- The cap is on the margin (30% of MRP), not a fixed price.
Mains, arguments and keywords:
- Trade margin rationalisation; out-of-pocket expenditure; non-scheduled drugs; supply-chain mark-up; availability safeguard.
Interview, be ready for:
- “Will capping margins make companies stop selling cancer drugs?” Weigh the production-maintenance rule and the 2019 experience against the risk of shortages.
Revision Cards
UjiyariThe 2019 precedent and next steps: card 3 →UjiyariTest yourself on card 4 →Show answer
Show answer
UjiyariTraps and recall on card 5 →R1Who finalises the list of drugs?
R2Who issues the notification?
R32019 precedent: how many drugs?
UjiyariWrite the Mains answer on card 6 →UjiyariNow take today’s quiz →Sources: PIB, Department of Pharmaceuticals, “Government Expands Cancer Medicine Price Controls; Cancer Patients Expected to Save ₹2,500 Crore Annually”, 8 October 2026; The Hindu, “Govt. to cap trade margins at 30% of MRP for cancer drugs”, 9 October 2026. Background: Current Affairs, 23 September 2026; Editorial, 1 October 2026.
Source: Cancer Drug Trade Margin Cap: 30% of MRP, NPPA and DPCO — Ujiyari.com | Free UPSC & State PCS Current Affairs
